-
LILT: A Novel Immune Checkpoint for Cancer Therapy(Post)
Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this gr
Etigilimab: Unveiling the Role of Anti-TIGIT in Cancer Research(Post)Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i
Sweet Deception: How a New Antibody Therapy Unmasks Pancreatic Cancer(Post)Sweet Deception: How a New Antibody Therapy Unmasks Pancreatic Cancer Sweet Deception: How a New Antibody Therapy Unmasks Pancreatic Cancer Pancreatic canc
A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics(Post)A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disease that has long puzzled researchers and clinicians. Howeve
Top 10 Universities in the UK(Post)Before I even started my PhD I was already thinking about carrying out PostDoc in a foreign country and had my sights set on going to the US. I had previously carried out a degree in Genetics
The Importance of Immunohistochemistry Training in Modern Scientific Research(Post)Immunohistochemistry (IHC) stands as a critical tool in the realm of biomedical research and diagnostic practices, offering a bridge between molecular insights and the intricate visualization of t
Biomarker Testing: Advancements, Applications, and Future Directions(Post)Biomarkers, measurable indicators of biological processes or responses to therapeutic interventions, play a pivotal role in modern healthcare. They provide clinicians with valuable information
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
Deciphering B Cell Cancers With a Rituximab Biosimilar(Post)The fight against B cell cancers, a challenging spectrum of hematologic malignancies, has entered a new era with the introduction of rituximab biosimilars. These biosimilars promise to extend the
Distributors(Page) Validación de kit ELISA: qué medir para confiar en los datos(Post)Validación de kit ELISA: qué medir para confiar en los datos Validar un kit ELISA significa demostrar, en la matriz y condiciones reales de trabajo, que cumple criterios de precisión, linealidad, sen
CRISPR-Cas Screening for Cell Viability(Post)Key Points Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a method of gene editing that uses t
एलिसा प्लेट धोने की युक्तियाँ(Page) What is the difference between PBS and dPBS?(Post)Lab Buffers · ProtocolsPBS vs DPBS: What’s the Difference?PBS and DPBS are the everyday isotonic, pH-balanced salt solutions used to wash, dilute and transport cells and proteins. This guide bre
Exploring the Frontier of Immunotherapy: T Cell Expansion(Post)In the realm of immunotherapy, T cell expansion has emerged as a pivotal strategy, holding promise in the treatment of various diseases, particularly cancer. T cells are a critical component of
Harnessing CD40 for Potent Anti-Tumor Immune Responses(Post)CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, plays a pivotal role in regulating immune responses, particularly in activating antigen-presenting cells (APCs) an
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Atezolizumab: Unveiling the Role of Anti-PD-L1 in Cancer Research(Post)Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's abili
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther